Amended Current Report Filing (8-k/a)
February 05 2016 - 5:30PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K/A
(Amendment no. 1)
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
January 29, 2016
Date of Report (Date of earliest event reported)
ELITE PHARMACEUTICALS, INC.
(Exact name of registrant as specified in
its charter)
Delaware |
001-15697 |
22-3542636 |
(State or other jurisdiction |
(Commission |
(IRS Employer |
of incorporation) |
File Number) |
Identification No.) |
165 Ludlow Avenue, Northvale, New Jersey
07647
(Address of principal executive offices)
(201) 750-2646
(Registrant’s telephone number, including
area code)
|
(Former name or former address, if changed since last report.) |
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
Explanatory Note
This Current Report on Form 8-K/A amends the Current Report
on Form 8-K filed by Elite Pharmaceuticals, Inc. (the "Company") on February 4, 2016 (the “Original 8-K”)
solely to file the letter from Demetrius Berkower LLC (“Demetrius”), which firm was dismissed as the Company’s
independent registered public accounting firm, addressed to the Securities and Exchange Commission stating whether Demetrius agrees
with certain statements made in the Original 8-K.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| 16.1 | Letter dated February 5, 2016, from Demetrius Berkower
LLC. to the Securities and Exchange Commission. |
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: February 5, 2016
|
ELITE PHARMACEUTICALS, INC. |
|
|
|
|
|
|
|
|
|
|
By: |
/s/ Nasrat Hakim |
|
|
Name: |
Nasrat Hakim |
|
|
Title: |
President & Chief Executive Officer |
|
February 5, 2016
Securities
and Exchange Commission
100 F Street, N.E.
Washington,
DC 20549
Ladies and Gentlemen:
We
have read Item 4.01 of Form 8-K dated January 29, 2016, of Elite Pharmaceuticals, Inc. and are in agreement with statements contained
in the second through fourth paragraphs of Item 4.01 therein.
We have no basis to agree or disagree with other statements of the registrant contained therein.
/s/ Demetrius
Berkower LLC
Demetrius Berkower
LLC
Wayne Plaza II,
155 Route 46, Wayne, NJ 07470-6831 • P (973) 812-0100 • F (973) 812-0750
517 Route One,
Iselin, NJ 08830 • P (732) 781-2712 • F (732) 781-2732
www.demetriusberkower.com
A PCAOB REGISTERED
FIRM
New
Jersey • California
|
Global
Support local Knowledge |
Elite Pharmaceuticals (QB) (USOTC:ELTP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Elite Pharmaceuticals (QB) (USOTC:ELTP)
Historical Stock Chart
From Apr 2023 to Apr 2024